PacBio soars on news of cheaper, smaller, higher-throughput sequencer

Pacific Biosciences ($PACB) has stepped up the fight for the sequencing market with the introduction of an instrument that is smaller, cheaper and higher throughput than the model it replaces. Roche ($RHHBY) has already signed up to use the instrument, named Sequel, as the basis for a tool it will deploy in clinical research. Shares in PacBio soared following the news, closing up 67% the day after it was released. The specifications of the sequencer also had an effect on perceptions of Illumina ($ILMN). Shares in the sequencing giant closed down 7% the day after the news--having dropped as much as 12% at one point--as investors sought to assess the likely impact of the instrument on its dominance. Release | opiniomics | Omics! Omics!

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.